How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

127 results for

Pancoast Tumor

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral Computerized Axial Tomography (CT) scan No tumor involving the superior sulcus (e.g., Pancoast tumor) Karnofsky performance status 70-100% Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 2 mg/dL Bilirubin < 2 mg/dL Aspartate aminotransferase (AST) < 3 times upper limit of normal Exclusion Criteria: Pregnant or nursing No nursing during and for ≥ 4 weeks after completion of study treatment Positive (...) to drug unavailability) First Posted : January 25, 2006 Results First Posted : December 3, 2009 Last Update Posted : December 28, 2017 Sponsor: Masonic Cancer Center, University of Minnesota Information provided by (Responsible Party): Masonic Cancer Center, University of Minnesota Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells

2006 Clinical Trials

102. Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy

have been amenorrheic at least for 12 months to be considered of non childbearing potential) Exclusion criteria: Presence of a Pancoast tumor Involvement of N2/N3 lymph nodes Distant metastases The following histological tumor types are excluded Pure bronchioloalveolar carcinoma Mixed cell carcinoma with small cell fractions Large Cell Carcinoma with areas of small cell carcinoma Pregnancy or lactation period Other co-existing malignancies or malignancies diagnosed within the last 5 years (...) of the tumor, where reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and hence perhaps survival. Pemetrexed, a folate antimetabolite, shows clear activity in non-small cell lung cancer with several Phase II studies of Pemetrexed in combination with Cisplatin, Oxaliplatin, or Carboplatin showing efficacy similar to other standard platinum doublets, with response rates of 27% to 45% and median survival of 8.9 to 10.9 months

2006 Clinical Trials

103. Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

. No positive supraclavicular or scalene lymph nodes extending up into the cervical region. No superior sulcus (pancoast tumors). No malignant pleural effusions. The only exception is a patient with a pleural effusion visible only on CT scan (and not visible on CXR) OR deemed too small to tap. No clinically significant or malignant pericardial effusions. No CNS metastases. No unintended weight loss (> 5% body weight) in the preceding 90 days prior to registration for initial therapy. No treatment with any (...) (Negative sorafenib results from ESCAPE trial and safety concerns of regimen) First Posted : December 29, 2006 Results First Posted : July 25, 2016 Last Update Posted : July 25, 2016 Sponsor: Nasser Hanna, M.D. Collaborators: Bayer Amgen Walther Cancer Institute Information provided by (Responsible Party): Nasser Hanna, M.D., Hoosier Cancer Research Network Study Details Study Description Go to Brief Summary: Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety

2006 Clinical Trials

104. Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

informed consent Exclusion Criteria: brain metastases squamous (epidermoid) histology hemoptysis central airway disease Pancoast tumors previous chemotherapy or biologic therapy for lung cancer prior malignancy within the previous 5 years except non-melanoma skin cancer or cervical CIS pregnant or nursing women Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact (...) : November 29, 2005 Sponsor: St. John Providence Health System Collaborators: Genentech, Inc. Eli Lilly and Company Information provided by: St. John Providence Health System Study Details Study Description Go to Brief Summary: this study is being done to find out if the combination of carboplatin and gemcitabine will be more effective in the the treatment of advanced lung cancer if bevacizumab, an agent that blocks tumor blood vessel formation, is added the study will measure the time to progression

2005 Clinical Trials

105. Molecular Profiling in Lung Cancer Patients

or radiation therapy for NSCLC (prior resection of lung is allowed provided at least 5 years have elapsed between prior surgery and enrolment) Exclusion Criteria: bronchoalveolar carcinoma or stage IIIA tumor involving the superior sulcus (Pancoast tumors) pregnant or breast feeding patients patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry patients with history or presence of other malignancy (...) to Brief Summary: The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in participants' blood and tumor tissue to see if there is any link between the levels or changes in the genes and how participants with lung cancer respond to pemetrexed and cisplatin treatment. Condition or disease Intervention/treatment Phase Non-Small Cell Lung

2005 Clinical Trials

106. Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung cancer Stage IIIA (T1-3, N2) or IIIB (N3) No clinical or radiographic evidence of supraclavicular lymph node involvement Pancoast tumors (...) : NCT00096226 Recruitment Status : Completed First Posted : November 9, 2004 Results First Posted : February 27, 2014 Last Update Posted : November 17, 2015 Sponsor: Radiation Therapy Oncology Group Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Radiation Therapy Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so

2004 Clinical Trials

107. Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

) Symptomatic tumors (T3, N0-1) involving the superior sulcus (i.e., Pancoast tumors) Measurable disease by contrast-enhanced CT scan No metastatic disease (except peribronchial or hilar lymph node involvement [N1]) by fludeoxyglucose F 18 PET scan No malignant pleural effusion by preoperative evaluation Pleural effusions visible only on CT scan that are not large enough for safe thoracentesis are allowed No exudative effusions (even if cytologically negative), as evidenced by any of the following: Ratio (...) Results First Posted : October 31, 2012 Last Update Posted : October 31, 2012 Sponsor: H. Lee Moffitt Cancer Center and Research Institute Collaborators: National Cancer Institute (NCI) AstraZeneca Information provided by (Responsible Party): H. Lee Moffitt Cancer Center and Research Institute Study Details Study Description Go to Brief Summary: RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink

2005 Clinical Trials

108. Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer

, primary bronchogenic non-small cell lung cancer meeting the following subtypes: Adenocarcinoma (no bronchioalveolar cell histology) Squamous cell carcinoma Large cell carcinoma Meeting the following staging criteria: Stage IIB (T2, N1, M0, or T3, N0, M0) Stage IIIA (T1-3, N2, M0 or T3, N1, M0) Stage IIIB (Any T, N3, M0 or T4, Any N, M0) No more than 1 parenchymal lesion in the same lung or in both lungs No tumor involving the superior sulcus (e.g., Pancoast tumor) Patients must undergo evaluation (...) Status : Terminated (Poor accrual) First Posted : September 17, 2007 Results First Posted : September 17, 2015 Last Update Posted : October 29, 2015 Sponsor: City of Hope Medical Center Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): City of Hope Medical Center Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either

2007 Clinical Trials

109. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. (PubMed)

patients), IIIB (10 patients), and IV (2 patients with isolated brain metastasis). Thirteen patients exhibited Pancoast tumors. Median time from completion of induction therapy to surgery was 53 days. Twenty-nine lobectomies and 11 pneumonectomies (7 right, 4 left) were performed. There were no postoperative deaths. Intercostal muscle flaps were used prophylactically in all but one pneumonectomy patient. Seven patients required perioperative transfusions. Median intensive care unit (ICU) time averaged

2004 Annals of Thoracic Surgery

110. Lung cancer. Special treatment issues. (PubMed)

Lung cancer. Special treatment issues. This chapter of the Lung Cancer Guidelines addresses patients with particular forms of non-small cell lung cancer that require special considerations. This includes patients with Pancoast tumors, T4N0,1M0 tumors, satellite nodules in the same lobe, synchronous and metachronous multiple primary lung cancers (MPLC), and solitary metastases. For patients with a Pancoast tumor, a multimodality approach, involving chemoradiotherapy and surgical resection (...) , appears optimal provided appropriate staging has been carried out. Patients with central T4 tumors that do not have mediastinal node involvement are uncommon. When carefully staged and selected, however, such patients appear to benefit from resection as part of the treatment as opposed to chemoradiotherapy alone. Patients with a satellite lesion in the same lobe as the primary tumor have a good prognosis and require no modification of the approach to evaluation and treatment from what would

2003 Chest

111. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). (PubMed)

Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). This chapter of the guidelines addresses patients who have particular forms of non-small cell lung cancer that require special considerations. This includes patients with Pancoast tumors, T4N0,1M0 tumors, satellite nodules in the same lobe, synchronous and metachronous multiple primary lung cancers (MPLCs), solitary brain and adrenal metastases, and chest wall involvement.The nature (...) by a standardized method (see "Methodology for Lung Cancer Evidence Review and Guideline Development" chapter), and reviewed by all members of the lung cancer panel before approval by the Thoracic Oncology NetWork, Health and Science Policy Committee, and the Board of Regents of the American College of Chest Physicians.In patients with a Pancoast tumor, a multimodality approach seems to be optimal, involving chemoradiotherapy and surgical resection, provided appropriate staging has been conducted. Patients

2007 Chest

112. Total spondylectomy for en bloc resection of lung cancer invading the chest wall and thoracic spine. Case report. (PubMed)

and posterior spinal instrumentation. At 46 months after surgery, there is no evidence of local recurrence or distant metastasis, and the patient continues to improve. This new procedure allows for the en bloc resection of primary lung tumors and adherent vertebral invasion without separation of the lesion from the vertebra. Thus, surgical management by complete excision of Pancoast tumors can achieve longer-term survival rates without sequelae. (...) Total spondylectomy for en bloc resection of lung cancer invading the chest wall and thoracic spine. Case report. Lung cancers invading the chest wall and spinal column are often considered unresectable, and consequently there are few reports describing resection of invasive vertebral lesions. The authors developed a new anterior approach procedure for the en bloc resection of primary lung adenocarcinoma invading the thoracic spine and chest wall, in which the primary tumor does not need

2004 Journal of Neurosurgery

113. Reflex sympathetic dystrophy associated with tumour infiltration of the stellate ganglion. (PubMed)

Reflex sympathetic dystrophy associated with tumour infiltration of the stellate ganglion. 8078053 1994 10 06 2018 11 13 0141-0768 86 8 1993 Aug Journal of the Royal Society of Medicine J R Soc Med Reflex sympathetic dystrophy associated with tumour infiltration of the stellate ganglion. 482-3 Olson W L WL Toledo Neurological Institute, Ohio 43537. eng Case Reports Journal Article England J R Soc Med 7802879 0141-0768 IM Adult Female Humans Male Neoplasm Invasiveness Neuroectodermal Tumors (...) complications pathology Pancoast Syndrome complications pathology Reflex Sympathetic Dystrophy etiology Stellate Ganglion pathology 1993 8 1 1993 8 1 0 1 1993 8 1 0 0 ppublish 8078053 PMC1294060 Arch Neurol. 1984 Aug;41(8):821-4 6466157 Z Lymphol. 1982 Dec;6(2):84-8 6188289 Neurology. 1980 May;30(5):534-5 7189258

Full Text available with Trip Pro

1993 Journal of the Royal Society of Medicine

114. Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

of the superior sulcus, chest wall, or mediastinum Must have at least 1 of the following: Locally advanced Pancoast tumors with no documented mediastinal or supraclavicular nodal involvement (T3-T4, N0-1) Resectable chest wall disease (T3, N0-1) Marginally resectable T4, N0-1, or NX central NSCLC N2 patients who are potentially resectable after induction chemoradiotherapy No evidence of extrathoracic spread to liver, adrenals, brain, or bone No evidence of supraclavicular nodes, malignant pleural (...) Last Update Posted : February 26, 2018 Sponsor: Fox Chase Cancer Center Information provided by (Responsible Party): Fox Chase Cancer Center Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving combination chemotherapy with radiation therapy before and after surgery may shrink the tumor so it can be removed

2002 Clinical Trials

115. SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer

: conventional surgery Radiation: low-LET cobalt-60 gamma ray therapy Phase 2 Detailed Description: OBJECTIVES: I. Assess the feasibility and toxic effects of 2 courses of cisplatin/etoposide given concurrently with continuous, fractionated chest irradiation followed by surgical resection and boost chemotherapy in patients with Pancoast tumors without mediastinal or supraclavicular nodal involvement. II. Assess the objective response rate, resectability rate, and proportion of patients free of microscopic (...) Lung Cancer Involving the Superior Sulcus (Pancoast Tumors): A Phase II Trial Study Start Date : April 1995 Actual Primary Completion Date : January 2001 Actual Study Completion Date : July 2004 Resource links provided by the National Library of Medicine related topics: related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: chemoradiotherapy followed by surgery chemoradiotherapy followed by surgery and post-surgery boost chemotherapy Drug: cisplatin 50 mg

1999 Clinical Trials

116. S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

surgical resection area No brain metastases No bronchoalveolar carcinoma or stage IIIB tumor involving the superior sulcus (pancoast tumors) PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Creatinine no greater than 2 times upper limit of normal AND Creatinine clearance at least 50 mL/min Other: No prior malignancy in the past 5 years except adequately treated basal cell or squamous cell (...) Update Posted : October 8, 2012 Sponsor: Southwest Oncology Group Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Southwest Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of two different combination

1999 Clinical Trials

117. S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically or cytologically confirmed, newly diagnosed, advanced primary non-small cell lung cancer (NSCLC) (adenocarcinoma, large cell carcinoma, squamous cell carcinoma, or unspecified), designated as 1 of the following stages: Selected stage IIIB (excluding Pancoast tumors) T4 lesion due to malignant pleural effusion OR Multiple lesions in a single lobe (...) , 2013 Sponsor: Southwest Oncology Group Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Southwest Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine followed by docetaxel in treating patients who have advanced non-small cell lung cancer. Condition or disease

2001 Clinical Trials

118. S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

) involving the superior sulcus No Pancoast's tumors Negative mediastinoscopy required in all patients with clinically positive mediastinal or hilar lymph nodes to ensure no N2 disease Bidimensionally measurable or evaluable disease by chest x-ray or contrast-enhanced CT scan T3, N0 disease assessable only by bronchoscopy must be affirmed by 2 observers and documented by photograph that includes main carina PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0 or 1 Life expectancy (...) Update Posted : January 31, 2013 Sponsor: Southwest Oncology Group Collaborators: National Cancer Institute (NCI) Eastern Cooperative Oncology Group North Central Cancer Treatment Group Radiation Therapy Oncology Group Information provided by (Responsible Party): Southwest Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more

1999 Clinical Trials

119. Posterior cervicothoracic instrumentation in spine tumors. (PubMed)

of 52 years. A total of 32 cervicothoracic instrumentations were performed. We used the R. Roy-Camille thoracolumbar plate in 20 patients, the cervico-thoracic plate in 8, and the Agora rod system in 4. In all, 96 lateral mass screws were implanted from C4 to C6, 54 into C7, and 180 pedicle screws from T1 to T8. Nineteen patients had lung cancer with vertebral body invasion (Pancoast tumors), 11 had metastasis to the cervicothoracic junction, 1 had a chondrosarcoma, and 1 had myeloma. In a first (...) Posterior cervicothoracic instrumentation in spine tumors. We retrospectively review 32 patients who underwent posterior fixation for cervicothoracic junctional tumors. All patients possessed unstable or potential after surgery unstable spines as a result of either their tumors or the surgery performed. We examined cervicothoracic spine stability, maintenance of alignment, and associated complications.To review our experience with 3 different posterior osteosynthesis systems applied

2004 Spine

120. Radical excision in the management of thoracic and cervicothoracic tumors involving the spine: results in a series of 36 cases. (PubMed)

Radical excision in the management of thoracic and cervicothoracic tumors involving the spine: results in a series of 36 cases. A new surgical technique for en bloc resection of posterior mediastinum tumors invading the spine is described.To demonstrate that major soft tissue tumors of the thoracic apex (Pancoast Tobias syndrome) or posterior mediastinum tumors can be removed en bloc even though the vertebral body or the foramina are invaded.En bloc surgery of tumor is accepted today as being (...) the goal of carcinologic surgery with the best results for survival. Until now, no surgical technique has been described for radical excision of soft tissue tumors invading the thoracic spine adjacent to the ribs and lung. We reviewed our 8 years' experience of 36 such cases and report outcome and survival rates.The authors have joined their abilities and technique to enable complete en bloc extratumoral resections of lung tumors or posterior mediastinum tumors invading the adjacent soft tissue

2003 Spine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>